Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mutant form of huntingtin protein (mHTT) arises from an expanded CAG trinucleotide repeat in the HTT gene, leading to an abnormally long polyglutamine tract. This causes Huntington’s disease (HD), characterized by motor dysfunction, psychiatric symptoms, and cognitive decline. mHTT aggregates, disrupts transcription, impairs DNA repair, activates apoptosis, and impairs intracellular trafficking, leading to neuronal dysfunction and neurodegeneration.
Inhibition of mHTT aggregation; modulation of splicing/expression levels
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Huntingtin protein mutant form (mHTT).